Cargando…

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era

BACKGROUND: Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pal, Sumanta K., Nelson, Rebecca A., Vogelzang, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643924/ https://www.ncbi.nlm.nih.gov/pubmed/23658823 http://dx.doi.org/10.1371/journal.pone.0063341

Ejemplares similares

Conditional Survival in de novo Metastatic Urothelial Carcinoma
por: Pal, Sumanta Kumar, et al.
Publicado: (2015)

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
por: Pal, Sumanta K, et al.
Publicado: (2012)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Role of cytokine therapy for renal cell carcinoma in the era of targeted agents
por: Koneru, R., et al.
Publicado: (2009)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Sequential Therapy in Metastatic Renal Cell Carcinoma
por: Hirsch, Bradford R., et al.
Publicado: (2016)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
por: Pal, Sumanta K., et al.
Publicado: (2019)

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy
por: Teishima, Jun, et al.
Publicado: (2021)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
por: Stenehjem, David D., et al.
Publicado: (2019)

Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents
por: Han, Jang Hee, et al.
Publicado: (2017)

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
por: Vogelzang, Nicholas J., et al.
Publicado: (2018)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
por: Abreu, Diego, et al.
Publicado: (2021)

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
por: Sazuka, Tomokazu, et al.
Publicado: (2015)

Biomarkers in renal cell carcinoma: Are we there yet?
por: Gulati, Shuchi, et al.
Publicado: (2021)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
por: Kawano, Yoshiaki, et al.
Publicado: (2016)

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
por: Li, Pengxiang, et al.
Publicado: (2015)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017)

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
por: Jürgens, Hannes, et al.
Publicado: (2020)

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy
por: Song, Yan, et al.
Publicado: (2016)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Renal cell carcinoma: An update for the practicing urologist
por: Pal, Sumanta K., et al.
Publicado: (2015)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0opf5ihq6gdf659fbrev7liv0c